Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.

Some people make it a New Year's resolution to improve their finances by investing in stocks. It's a laudable goal, and to get started, it's crucial to pick stocks that have the tools to perform well for decades to come. Corporations that fit this criteria are a rare breed, but they do exist.

Below, I'll look at two companies in the healthcare sector: Eli Lilly (NYSE: LLY) and Vertex Pharmaceuticals (NASDAQ: VRTX). For those with $5,000 to invest that's not being saved for routine expenses or emergencies, purchasing shares of these two companies could be a great move.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »

1. Eli Lilly

Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several headwinds, including the fact that it didn't meet investors' sky-high expectations.

The company's third-quarter revenue grew by 20% year over year to $11.4 billion, a terrific performance for almost any other pharmaceutical company. However, Eli Lilly missed analyst estimates for the period, sending its stock price down. However, these short-term issues mean little for the company's long-term prospects.

Over the past few years, Eli Lilly has demonstrated that it's an innovative company. The drugmaker developed several breakthrough medicines, including tirzepatide, its famous diabetes and weight loss management treatment that was the first dual GLP-1/GIP to earn approval from the U.S. Food and Drug Administration. It also launched Kisunla, one of the few Alzheimer's disease treatments to get the green light in the last two decades, earning this therapeutic area the label of the "graveyard" of investigational medicines.

These (and other) products should drive top-line growth for Eli Lilly well into the 2030s. The healthcare giant has several exciting late-stage pipeline candidates, too, especially in the weight loss market. Eli Lilly's long, successful history of dominating the diabetes market is more important than any specific drug or pipeline program.

This doesn't happen by accident. The company has created and fostered an internal culture of innovation honed by many successes (and failures) over decades. That's what should allow Eli Lilly to continue producing billion-dollar drugs, excellent financial results, and market-beating performances.

For income-oriented investors, Eli Lilly has a solid dividend program, too. All things considered, the company is an excellent forever stock to invest in -- and $5,000 will get you six shares with change left over.

2. Vertex Pharmaceuticals

Vertex Pharmaceuticals is well-known for developing and marketing drugs that treat cystic fibrosis (CF), a rare genetic condition that damages patients' lungs. It was the first company to create approved medicines that target the underlying causes of CF, rather than just treating some symptoms of the disease. Since the approval of Vertex's first CF medicine in 2012, no other company has cracked this code, despite plenty of them trying.

That's no small feat. It's no surprise, then, that Vertex's revenue and earnings have grown rapidly in the past decade.

VRTX Revenue (Annual) data by YCharts.

The question for investors is whether Vertex's work in CF was an anomaly -- a one-off that the company can't reproduce in other areas -- but the evidence suggests otherwise. In 2023, Vertex earned approval for Casgevy, a gene-editing treatment for two rare blood-related conditions with very few treatment options.

Vertex Pharmaceuticals didn't create Casgevy itself -- that was CRISPR Therapeutics' accomplishment. However, that should mean little to investors. Penning lucrative deals with smaller drugmakers is a legitimate strategy that larger companies resort to all the time. Further, Vertex has exciting pipeline candidates of its own. It could earn approval for suzetrigine, a treatment for acute pain, by the end of the month.

Its late-stage pipeline features inaxaplin, a potential therapy for APOL-1-mediated kidney disease (there are currently no treatments that target its underlying causes). Vertex's early-stage type 1 diabetes candidate is also making strides.

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's another excellent stock to buy and hold for good. At the stock's current levels, investors can acquire 11 shares of the company with $5,000.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $369,816!*
• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $42,191!*
• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $527,206!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Learn more »

*Stock Advisor returns as of January 21, 2025

Prosper Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.